Bone Metastasis — Med2Date

📋 Key Information Summary

📋

Bone is the third most common site of metastatic disease after lung and liver; skeletal metastases are found in up to 70 % of patients dying from breast, prostate, or lung cancer at autopsy.
The most frequent primary tumours metastasising to bone in Australia are breast (65–75 %), prostate (65–75 %), lung (30–40 %), kidney (20–25 %), and thyroid (20–40 %).
Axial skeleton is preferentially involved owing to haematogenous spread via Batson venous plexus; common sites include vertebrae, pelvis, ribs, proximal femur, and proximal humerus.
Skeletal-related events (SREs) — pathological fracture, spinal cord compression, hypercalcaemia, bone pain requiring radiotherapy, and need for orthopaedic surgery — dramatically reduce quality of life.
Bone pain is the presenting complaint in 70–80 %; suspect metastasis in any cancer patient with new skeletal pain, especially nocturnal or rest pain.
99mTc bone scintigraphy remains the first-line screening investigation; whole-body MRI has superior sensitivity for marrow infiltration and spinal cord compression.
18F-FDG PET/CT is the single most sensitive and specific modality for lytic metastases and staging; PBS-rebated for eligible indications under MBS item 61522.
Zoledronic acid 4 mg IV every 3–4 weeks and denosumab 120 mg SC every 4 weeks are the two antiresorptive agents with Level I evidence for SRE prevention; both are PBS Authority Required.
Single-fraction radiotherapy (8 Gy) provides equivalent pain relief to multi-fraction regimens for most symptomatic bone metastases and is the preferred Australian standard.
Hypofractionated stereotactic body radiotherapy (SBRT) is increasingly used for oligometastatic disease with spinal or weight-bearing involvement.
Emergent surgical stabilisation is indicated for impending or completed long-bone fracture and unstable spinal metastases; multidisciplinary bone metastasis clinics improve outcomes.
Adequate pain control follows the WHO analgesic ladder; opioid initiation should be guided by the Therapeutic Goods Administration frameworks and real-time prescription monitoring (SafeScript).
Dental assessment prior to antiresorptive therapy is mandatory to reduce osteonecrosis of the jaw (ONJ) risk.
Aboriginal and Torres Strait Islander patients present with more advanced disease and have lower utilisation of bone-directed therapies; culturally safe, shared-care pathways are essential.

Introduction & Australian Epidemiology

Bone metastases represent one of the most frequent and debilitating complications of advanced malignancy. They cause significant morbidity through pain, pathological fracture, hypercalcaemia, and spinal cord compression, collectively termed skeletal-related events (SREs). In Australia, approximately 50 000 patients live with or are diagnosed with metastatic disease annually, and up to 70 % of those dying from breast, prostate, or lung cancer harbour skeletal deposits at autopsy.

The economic burden is substantial: a single SRE costs the Australian health system an estimated AUD 15 000–30 000 in hospitalisation, surgery, and radiotherapy. Improved systemic therapies have prolonged survival in many metastatic cancers, increasing the population at risk for SREs and making bone-directed therapy a growing component of cancer care.

The most common primary malignancies that metastasise to bone, in descending frequency, are breast, prostate, lung, kidney, and thyroid. Haematological malignancies — particularly multiple myeloma — also commonly produce destructive skeletal lesions and are discussed in related guidelines.

Primary Tumour	Frequency of Bone Metastasis	Predominant Pattern
Breast	65–75 %	Mixed osteolytic / osteoblastic
Prostate	65–75 %	Predominantly osteoblastic
Lung	30–40 %	Predominantly osteolytic
Kidney (RCC)	20–25 %	Expansile osteolytic
Thyroid	20–40 %	Osteolytic
Melanoma	15–20 %	Osteolytic

⚠️

Any cancer patient presenting with new, unexplained skeletal pain should be investigated for bone metastasis promptly. Delays of >4 weeks increase the risk of pathological fracture and spinal cord compression.

Pathophysiology & Common Primary Tumours

Haematogenous Spread

The axial skeleton and proximal long bones are preferentially involved because tumour cells enter the paravertebral venous plexus (Batson plexus), a valveless network that communicates freely with pelvic, thoracic, and cranial venous drainage. Retrograde flow during raised intra-abdominal pressure seeds tumour cells into vertebral marrow.

The "Seed and Soil" Hypothesis

Bone marrow provides a fertile microenvironment — rich in growth factors such as IGF-1, TGF-β, BMPs, and calcium — that promotes tumour dormancy escape and proliferation. Specific integrins (αvβ3, αvβ5) and chemokine receptors (CXCR4) on tumour cells mediate homing to stromal cell-derived factor-1 (SDF-1/CXCL12) expressed by osteoblasts and endothelial cells in marrow.

Vicious Cycle of Bone Destruction

In osteolytic metastases (breast, lung, kidney), tumour cells secrete parathyroid-hormone-related peptide (PTHrP), IL-6, IL-11, and RANKL, which stimulate osteoclast differentiation and activity via the RANK/RANKL/OPG pathway. Released bone matrix factors (TGF-β, IGF-1) in turn stimulate tumour growth, creating a self-perpetuating "vicious cycle."

Osteoblastic vs Osteolytic Metastases

Prostate cancer typically produces osteoblastic metastases through secretion of endothelin-1, BMPs, and Wnt ligands that activate osteoblast precursors. However, histomorphometric studies confirm that osteoclast activity is also increased in osteoblastic lesions, and antiresorptive therapy remains beneficial. Most metastases have mixed features.

🔬

The RANK/RANKL/OPG axis is the central therapeutic target for bone-directed agents: denosumab is a fully human monoclonal antibody against RANKL, while bisphosphonates inhibit osteoclast function via the mevalonate (farnesyl pyrophosphate synthase) pathway.

Clinical Features & Skeletal-Related Events

Presenting Features

Bone pain (70–80 %): The most common symptom; progressive, nocturnal, and exacerbated by weight-bearing. Localised tenderness over a long bone suggests impending fracture.
Pathological fracture (8–30 %): Often the first presentation. The femoral neck and shaft, humerus, and vertebrae are most commonly affected.
Hypercalcaemia (10–20 %): Presents with polyuria, polydipsia, constipation, confusion, and shortened QTc. More common with osteolytic metastases, especially lung and renal cell carcinoma.
Spinal cord compression (5–10 %): An oncological emergency. Thoracic spine is most commonly affected. Back pain, progressive limb weakness, sensory level, and bladder/bowel dysfunction.
Neurological compromise: Cauda equina syndrome from lumbosacral disease, brachial plexopathy from apical lung or breast metastases.
Marrow failure: Anaemia, thrombocytopenia, leucoerythroblastic picture on blood film when extensive marrow replacement occurs.

Definition of Skeletal-Related Events (SREs)

SREs are the composite endpoint used in clinical trials of bone-directed therapies:

Pathological fracture (vertebral or non-vertebral)
Spinal cord compression
Requirement for radiotherapy to bone for pain relief or impending fracture
Requirement for orthopaedic surgery to bone
Hypercalcaemia of malignancy (some trial definitions)

🚨

Spinal cord compression is an oncological emergency. Suspect in any cancer patient with new back pain (especially thoracic), limb weakness, sensory level, or bladder dysfunction. Obtain urgent MRI whole spine and involve radiation oncology and neurosurgery within 24 hours. Early treatment (surgery or radiotherapy within 24 h) significantly improves ambulation rates.

Mirels Classification — Fracture Risk

Criterion	1 Point	2 Points	3 Points
Site	Upper limb	Lower limb	Peritrochanteric
Pain	Mild	Moderate	Functional
Lesion type	Blastic	Mixed	Lytic
Size (cortical involvement)	< 1/3	1/3 – 2/3	> 2/3

Interpretation: Score ≥ 9 = high fracture risk (≥ 33 % probability within 6 months) — prophylactic surgical stabilisation is recommended.

Investigations (Bone Scan, PET & MRI)

Imaging Modalities

Essential

99mTc Whole-Body Bone Scintigraphy (Bone Scan)

First-line screening investigation for suspected bone metastases. Sensitivity 62–100 %, specificity 78–100 %. Highly sensitive for osteoblastic lesions (prostate, breast); less sensitive for purely lytic lesions (myeloma, RCC) and early marrow disease. MBS item 61403 (Medicare rebate ~AUD 320). Scan-meets-scan approach or SPECT/CT improves specificity.

Available

18F-FDG PET/CT

Superior sensitivity for lytic metastases and marrow infiltration. Single most useful modality for staging in many cancers. PBS-rebated under MBS item 61522 (Authority Required for approved indications including lymphoma, lung, oesophageal, melanoma staging). Sensitivity 95–100 % for osteolytic, 50–70 % for osteoblastic lesions. 68Ga-PSMA PET/CT is now the standard for prostate cancer staging (MBS item 61522).

Available

Whole-Body MRI (Diffusion-Weighted)

Highest sensitivity for early marrow infiltration (near 100 %). Gold standard for spinal cord compression assessment. Recommended when bone scan is equivocal or when spinal metastases/cord compression is suspected. MBS item 63524 (Medicare rebate available for spinal indications). Typically available in major metropolitan centres.

Available

CT of Affected Region

Useful for characterising cortical integrity, planning surgical fixation, and guiding biopsy. CT-guided bone biopsy has diagnostic yield >90 % when histological confirmation is required.

Available

Plain Radiographs

First-line investigation for focal bone pain. Required to assess cortical destruction for Mirels scoring. Must be obtained in two planes including the joint above and below. Cost-effective but low sensitivity for early metastasis.

Laboratory Investigations

Serum calcium (corrected for albumin): Screen for hypercalcaemia. Repeat ionised calcium if borderline.
Serum alkaline phosphatase (ALP): Elevated in osteoblastic metastases; may be normal in purely lytic disease.
Tumour markers: PSA (prostate), CA 15-3 / CA 27-29 (breast), CEA (colorectal) — context-dependent.
FBC: Leucoerythroblastic anaemia suggests extensive marrow infiltration.
Renal function (eGFR): Mandatory before zoledronic acid dose adjustment.
Serum NTx or CTx: Bone turnover markers may guide antiresorptive therapy response but are not routine in clinical practice.
Calcium, phosphate, PTH, 25-OH vitamin D: Assess for hypercalcaemia aetiology and vitamin D status prior to bisphosphonate therapy.

⚠️

Do not commence zoledronic acid or denosumab without confirming corrected calcium is within the normal range. Severe hypocalcaemia can develop within 24–48 hours if pre-existing vitamin D deficiency and hypocalcaemia are uncorrected.

Risk Stratification & Severity Scoring

Risk stratification guides decisions about prophylactic surgery, antiresorptive therapy intensity, and radiotherapy planning. The Mirels score (see Clinical Features section) is the standard tool for long-bone fracture risk.

Low Risk

Asymptomatic / Indolent

Mirels ≤ 7; single asymptomatic lesion found incidentally on staging; no cortical compromise > 1/3; blastic subtype. Responsive primary (e.g. hormone-receptor positive breast).

Setting: Outpatient — antiresorptive therapy, surveillance imaging, radiotherapy if symptomatic

Moderate Risk

Symptomatic / Increasing Lesion Size

Mirels 8; painful metastases with 1/3–2/3 cortical involvement; mixed lytic/blastic; multiple sites; rising tumour markers. No neurological deficit.

Setting: Outpatient / day-case — consider SBRT, prophylactic surgery discussion at MDT, antiresorptive therapy

High Risk

Impending Fracture / Neurological Compromise

Mirels ≥ 9; cortical destruction > 2/3; functional pain; spinal metastasis with epidural disease or neurological deficit; completed pathological fracture; hypercalcaemia.

Setting: Inpatient — urgent orthopaedic or neurosurgical referral; emergency radiotherapy for cord compression

🚨

Mirels score ≥ 9: Prophylactic intramedullary nailing or endoprosthetic reconstruction should be performed before fracture occurs. Surgical outcomes are significantly better for prophylactic fixation than post-fracture fixation.

Management — Antiresorptive Therapy

Bisphosphonates — Zoledronic Acid

💊

Zoledronic Acid

Zometa® · Aclasta® (osteoporosis strength) · Bisphosphonate (nitrogen-containing)

Adult dose 4 mg IV over ≥ 15 min every 3–4 weeks

Paediatric dose Not established for bone metastasis indication in paediatrics

Route Intravenous infusion

Frequency Every 3–4 weeks

Duration Continue while patient has active skeletal metastases and life expectancy > 3 months

Renal adjustment eGFR 50–60: 3.5 mg; eGFR 40–49: 3.3 mg; eGFR 30–39: 3.0 mg; eGFR < 30: contraindicated

Hepatic adjustment No dose adjustment required

PBS status Authority Required — bone metastases from breast cancer, prostate cancer (castration-resistant), myeloma

Denosumab — RANK-L Inhibitor

💊

Denosumab

Xgeva® · Fully human anti-RANKL monoclonal antibody

Adult dose 120 mg SC every 4 weeks (into thigh, abdomen, or upper arm)

Paediatric dose Not established for bone metastasis indication; used in giant cell tumour of bone at 120 mg SC q4w (with loading doses)

Route Subcutaneous injection

Renal adjustment None required — advantage over zoledronic acid in renal impairment (eGFR < 30). Monitor calcium closely.

PBS status Authority Required — bone metastases from solid tumours (breast, prostate, lung, others). Not PBS-listed for myeloma.

⚠️

Dental assessment before commencing antiresorptive therapy. Osteonecrosis of the jaw (ONJ) incidence is 1–10 %. Risk increases with duration of therapy, dental extractions, poor oral hygiene, and concurrent corticosteroids. All patients should undergo dental examination and complete any invasive dental procedures before starting therapy. Educate patients on oral hygiene and regular dental review.

Hypocalcaemia Prevention

Both zoledronic acid and denosumab can cause severe hypocalcaemia. Ensure:

Calcium and vitamin D levels are checked before first dose
Supplement with calcium 500 mg + cholecalciferol 500 IU BD (e.g. Cal-D) if 25-OH vitamin D < 50 nmol/L
Monitor serum calcium at 1–2 weeks after first dose, especially in patients with eGFR < 60

Management — Radiotherapy & Surgery

Radiotherapy for Bone Metastases

✅

Australian standard: Single-fraction radiotherapy (8 Gy × 1) provides equivalent pain relief to multi-fraction regimens for most symptomatic bone metastases. It is more convenient, reduces patient travel burden (especially in regional and remote Australia), and is the recommended first-line approach per RANZCR and eviQ guidelines.

Indication	Regimen	Notes
Pain relief (standard)	8 Gy × 1 fraction	Preferred first-line. Equivalent pain relief to 30 Gy / 10 fractions.
Pain relief (re-treatment)	8 Gy × 1 fraction (if prior Rx > 3 months ago)	Can re-treat if adequate interval. Consider SBRT if conventional RT exhausted.
Spinal cord compression (palliative)	30 Gy / 10 fractions or 20 Gy / 5 fractions	Commence dexamethasone 16 mg immediately; surgery considered if single-level, non-radiosensitive tumour, good performance status.
Impending fracture (long bone)	8 Gy × 1 or 20 Gy / 5 fractions	Surgical stabilisation usually preferred for Mirels ≥ 9; RT post-operatively.
Oligometastatic disease / curative intent	SBRT 24–30 Gy / 3–5 fractions	Requires specialist planning; local control 80–90 %. For limited metastases (< 5) with controlled primary.

Surgical Management

Surgery is indicated for mechanical instability, completed pathological fracture, and spinal metastases causing neurological compromise or instability.

1

Long-Bone Metastasis

Prophylactic intramedullary nailing (femur, humerus) or endoprosthetic replacement for Mirels ≥ 9. Post-fixation radiotherapy within 4–6 weeks reduces hardware failure risk. Avoid plate-and-screw fixation (high failure rate due to tumour-softened bone).

2

Pathological Fracture — Long Bone

Stabilise with intramedullary nail or endoprosthesis. Aim for weight-bearing as soon as feasible. Coordinate with radiotherapy post-operatively.

3

Spinal Metastasis — Surgical Candidates

Decompression ± stabilisation for single-level disease, good performance status (ECOG 0–2), radioresistant tumour (RCC, melanoma, thyroid), or spinal instability. Posterior decompression with instrumented fusion is the standard approach. Surgery + RT is superior to RT alone for selected patients (Patchell criteria).

4

Pelvic Metastases

Acetabular lesions with medial migration may require percutaneous cementoplasty (cement augmentation) or reconstruction with a cage + cemented total hip replacement. Pelvic radiotherapy is effective for pain control without surgery in non-weight-bearing areas.

⚠️

Perioperative considerations: Surgical risk assessment must consider prognosis (expected survival > 4–6 weeks for benefit), performance status, anaemia, nutritional status, and coagulopathy. Antiresorptive therapy should be withheld for 4–6 weeks around major orthopaedic surgery to reduce ONJ and wound-healing complications.

Monitoring

Parameter	Frequency	Purpose
Serum calcium (corrected)	Baseline; 1–2 weeks post-first dose; then periodically	Detect hypocalcaemia from antiresorptive therapy
Serum creatinine / eGFR	Before each zoledronic acid infusion	Dose adjustment / withhold if significant decline
Serum ALP	Every 4–8 weeks	Surrogate marker of osteoblastic response to therapy
25-OH vitamin D	Baseline; 3-monthly if supplementing	Maintain > 50 nmol/L to reduce hypocalcaemia risk
Pain score (NRS 0–10)	Every clinic visit	Assess treatment response; adjust analgesia
Functional status (ECOG)	Every clinic visit	Guide surgical vs palliative decisions
Dental review	6-monthly during antiresorptive therapy	Early detection of ONJ
Imaging (bone scan or PET/CT)	Every 3–6 months or as clinically indicated	Assess disease burden; detect new sites

ℹ️

Long-term bisphosphonate reassessment: After 2 years of monthly zoledronic acid, consider extending the interval to every 3 months for responding patients. A landmark trial (Himelstein et al., JAMA 2017) showed non-inferiority of every-12-week dosing vs every-4-week dosing for metastatic breast cancer, with fewer adverse events.

Special Populations

🤰 Pregnancy

Zoledronic acid

Contraindicated in pregnancy (Category D). Bisphosphonates cross the placenta and accumulate in fetal bone. Effective contraception required during and for 6 months after cessation.

Denosumab

Contraindicated in pregnancy. May cause fetal harm including skeletal malformations. Effective contraception required.

Radiotherapy

Requires careful shielding and dose planning. Abdominal/pelvic RT contraindicated in pregnancy; may require termination discussion in first trimester if essential therapy.

👶 Paediatrics

Bone metastases

Rare in paediatric solid tumours (osteosarcoma, Ewing sarcoma may have skip metastases). Management is via paediatric oncology MDT. Bisphosphonates used off-label for bone pain in paediatric palliative care at reduced doses.

👴 Elderly (≥ 70 years)

Antiresorptive therapy

Increased ONJ and atypical femoral fracture risk with prolonged use. Monitor renal function closely. Consider treatment goals (palliation vs prolongation of life) in context of frailty and comorbidities.

Surgery

Higher perioperative morbidity. Pre-operative geriatric assessment recommended. Early mobilisation protocols improve outcomes.

🫘 Renal Impairment

Zoledronic acid

Contraindicated if eGFR < 30. Dose reduction required for eGFR 30–60 (see dosing table). Infusion time ≥ 30 minutes if eGFR < 60. Monitor creatinine before each dose; withhold if > 0.5 mg/dL rise from baseline.

Denosumab

Preferred agent in severe renal impairment (eGFR < 30) as it is not renally cleared. However, risk of severe hypocalcaemia is greatly increased — ensure adequate calcium/vitamin D supplementation and monitor calcium weekly for first month.

🫁 Hepatic Impairment

Zoledronic acid / Denosumab

No dose adjustment required. However, patients with hepatic metastases may have altered drug metabolism for concurrent systemic chemotherapy. Vitamin D activation is impaired in severe liver disease — supplement with cholecalciferol (25-OH form is not available on PBS).

🛡️ Immunocompromised

Infection risk

Antiresorptive therapy does not significantly increase infection risk. However, dental procedures in immunocompromised patients on antiresorptive therapy carry higher ONJ risk. Prophylactic antibiotics may be considered for dental extractions in this group.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Cancer stage at presentation

Aboriginal and Torres Strait Islander peoples are more likely to present with advanced-stage cancer and bone metastases at diagnosis. Data from the AIHW Cancer in Aboriginal and Torres Strait Islander peoples report (2023) show that Indigenous Australians have 1.5–2 times the rate of distant-stage presentation for breast, prostate, and lung cancer compared to non-Indigenous Australians.

Access to specialist oncology care

Significant barriers exist for Indigenous Australians in rural and remote communities to access radiation oncology (limited to metropolitan and major regional centres), PET/CT (concentrated in capital cities), and specialist bone metastasis MDTs. Telehealth oncology consultations have improved access since 2020 but remain underutilised.

Antiresorptive therapy uptake

Studies from Cancer Australia show lower rates of bisphosphonate and denosumab use among Indigenous cancer patients, even after adjusting for stage and comorbidity. Contributing factors include fragmented follow-up, travel burden for IV infusions, and limited community pharmacy access for SC denosumab in remote areas.

Dental health and ONJ risk

Aboriginal and Torres Strait Islander peoples have higher rates of dental disease and limited access to dental services, which increases the risk of osteonecrosis of the jaw with antiresorptive therapy. Pre-treatment dental assessment is critical but access remains a major barrier in many communities. Collaboration with Aboriginal Community Controlled Health Organisation (ACCHO) dental services is recommended.

Pain management

Real-time prescription monitoring (SafeScript) and opioid regulatory frameworks may disproportionately affect Indigenous patients in rural/remote areas where specialist pain services are unavailable. Culturally safe pain management plans should be developed in partnership with local Aboriginal Health Workers and Elders.

Recommended actions

• Implement shared-care pathways between metropolitan bone metastasis MDTs and regional/remote Indigenous cancer services. • Support Aboriginal Health Workers with bone metastasis education (Cancer Australia resources). • Facilitate home-based or community-administered denosumab where IV zoledronic acid access is limited. • Ensure culturally appropriate end-of-life care and advanced care planning are offered early. • Use AIHW and Cancer Australia data to monitor and reduce inequities in bone-directed therapy access.

📚 References

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–6249s.
2. Coleman RE, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–iii137.
3. Mirels H. Metastatic disease in long bones: a proposed scoring system for treating impending pathologic fractures. Orthop Clin North Am. 2000;31(4):593–601.
4. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III, double-blind, randomized trial. J Clin Oncol. 2003;21(16):3150–3157.
5. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139.
6. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822.
7. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48–58.
8. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–648.
9. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24(2):112–124.
10. Royal Australian and New Zealand College of Radiologists (RANZCR). EviQ Cancer Treatments: Palliative Radiotherapy for Bone Metastases. eviQ; 2024. Available at: eviq.org.au.
11. Cancer Australia. National Cancer Control Indicators: Cancer in Aboriginal and Torres Strait Islander Peoples of Australia. Surry Hills, NSW: Cancer Australia; 2023.
12. Australian Institute of Health and Welfare (AIHW). Cancer in Aboriginal & Torres Strait Islander people of Australia. Canberra: AIHW; 2023.
13. Khan L, Raman S, Ngoc Nguyen T, et al. Radiotherapy for bone metastases: a systematic review. Clin Oncol (R Coll Radiol). 2021;33(11):e524–e535.
14. Saad F, Ivanescu C, Phung D, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer Prostatic Dis. 2017;20(1):110–116.
15. Hughes D. Denosumab: an Australian perspective. Aust Prescr. 2012;35(5):152–156.